<!DOCTYPE pdf2xml SYSTEM "pdf2xml.dtd">
<pdf2xml producer="poppler" version="23.04.0">
<page number="1" position="absolute" top="0" left="0" height="792" width="612">
	<fontspec id="font0" size="11" family="Helvetica-Black,Bold" color="#ffffff"/>
	<fontspec id="font1" size="8" family="AkzidenzGroteskBE,Bold" color="#000000"/>
	<fontspec id="font2" size="8" family="AkzidenzGroteskBE-Md,Bold" color="#000000"/>
	<fontspec id="font3" size="8" family="AkzidenzGroteskBE" color="#000000"/>
	<fontspec id="font4" size="7" family="AkzidenzGroteskBE-It,Italic" color="#000000"/>
	<fontspec id="font5" size="2" family="AkzidenzGroteskBE" color="#ffffff"/>
	<fontspec id="font6" size="15" family="AkzidenzGroteskBE" color="#000000"/>
	<fontspec id="font7" size="16" family="AkzidenzGroteskBE,Bold" color="#000000"/>
	<fontspec id="font8" size="11" family="AkzidenzGroteskBE,Bold" color="#000000"/>
	<fontspec id="font9" size="16" family="AkzidenzGroteskBE,BoldItalic" color="#000000"/>
	<fontspec id="font10" size="12" family="AkzidenzGroteskBE" color="#000000"/>
	<fontspec id="font11" size="8" family="AkzidenzGroteskBE-It,Italic" color="#000000"/>
	<fontspec id="font12" size="9" family="AkzidenzGroteskBE-Md,Bold" color="#000000"/>
	<fontspec id="font13" size="9" family="AkzidenzGroteskBE" color="#000000"/>
	<fontspec id="font14" size="6" family="AkzidenzGroteskBE" color="#000000"/>
	<fontspec id="font15" size="9" family="AkzidenzGroteskBE-It,Italic" color="#000000"/>
<text top="85" left="477" width="78" height="10" font="font0" id="p1_t1" reading_order_no="2" segment_no="1" tag_type="title"><a href="http://www.biomedcentral.com/info/about/charter/"><b>Open Access</b></a></text>
<text top="42" left="315" width="62" height="7" font="font1" id="p1_t2" reading_order_no="0" segment_no="0" tag_type="text"><b>Available online</b></text>
<text top="42" left="380" width="176" height="7" font="font3" id="p1_t3" reading_order_no="1" segment_no="0" tag_type="text">http://breast-cancer-research.com/content/8/6/R63</text>
<text top="758" left="509" width="45" height="7" font="font3" id="p1_t4" reading_order_no="151" segment_no="21" tag_type="text">Page 1 of 10</text>
<text top="769" left="434" width="120" height="6" font="font4" id="p1_t5" reading_order_no="152" segment_no="22" tag_type="text"><i>(page number not for citation purposes)</i></text>
<text top="85" left="57" width="9" height="2" font="font5" id="p1_t6" reading_order_no="4" segment_no="2" tag_type="title">Vol 8 No 6</text>
<text top="85" left="57" width="103" height="14" font="font6" id="p1_t7" reading_order_no="3" segment_no="2" tag_type="title">Research article</text>
<text top="102" left="57" width="360" height="14" font="font7" id="p1_t8" reading_order_no="5" segment_no="3" tag_type="title"><b>Suppression of breast cancer cell growth by Na</b></text>
<text top="101" left="417" width="7" height="10" font="font8" id="p1_t9" reading_order_no="6" segment_no="3" tag_type="title"><b>+</b></text>
<text top="102" left="425" width="20" height="14" font="font7" id="p1_t10" reading_order_no="7" segment_no="3" tag_type="title"><b>/H</b></text>
<text top="101" left="444" width="10" height="10" font="font8" id="p1_t11" reading_order_no="8" segment_no="3" tag_type="title"><b>+ </b></text>
<text top="102" left="455" width="84" height="14" font="font7" id="p1_t12" reading_order_no="9" segment_no="3" tag_type="title"><b>exchanger </b></text>
<text top="120" left="57" width="151" height="14" font="font7" id="p1_t13" reading_order_no="10" segment_no="3" tag_type="title"><b>regulatory factor 1 (</b></text>
<text top="120" left="207" width="64" height="14" font="font9" id="p1_t14" reading_order_no="11" segment_no="3" tag_type="title"><i><b>NHERF1</b></i></text>
<text top="120" left="272" width="6" height="14" font="font7" id="p1_t15" reading_order_no="12" segment_no="3" tag_type="title"><b>)</b></text>
<text top="138" left="57" width="180" height="11" font="font10" id="p1_t16" reading_order_no="13" segment_no="4" tag_type="text">Yong Pan, Lei Wang and Jia Le Dai</text>
<text top="171" left="57" width="472" height="7" font="font3" id="p1_t17" reading_order_no="14" segment_no="5" tag_type="text">Department of Molecular Pathology, The University of Texas M. D. Anderson Cancer Center, 7435 Fannin Street, Houston, TX 77054, USA</text>
<text top="189" left="57" width="192" height="7" font="font3" id="p1_t18" reading_order_no="15" segment_no="6" tag_type="text">Corresponding author: Jia Le Dai, jldai@mdanderson.org</text>
<text top="207" left="57" width="481" height="7" font="font3" id="p1_t19" reading_order_no="16" segment_no="7" tag_type="text">Received: 17 Jul 2006 Revisions requested: 21 Aug 2006 Revisions received: 4 Sep 2006 Accepted: 1 Nov 2006 Published: 1 Nov 2006</text>
<text top="226" left="57" width="85" height="7" font="font11" id="p1_t20" reading_order_no="17" segment_no="8" tag_type="text"><i>Breast Cancer Research</i></text>
<text top="226" left="141" width="25" height="7" font="font3" id="p1_t21" reading_order_no="18" segment_no="8" tag_type="text"> 2006, </text>
<text top="226" left="166" width="4" height="7" font="font2" id="p1_t22" reading_order_no="19" segment_no="8" tag_type="text"><b>8</b></text>
<text top="226" left="171" width="99" height="7" font="font3" id="p1_t23" reading_order_no="20" segment_no="8" tag_type="text">:R63 (doi:10.1186/bcr1616)</text>
<text top="236" left="57" width="256" height="7" font="font3" id="p1_t24" reading_order_no="21" segment_no="9" tag_type="text"><a href="http://breast-cancer-research.com/content/8/6/R63">This article is online at: http://breast-cancer-research.com/content/8/6/R63</a></text>
<text top="246" left="57" width="43" height="7" font="font3" id="p1_t25" reading_order_no="22" segment_no="10" tag_type="text">Â© 2006 Pan</text>
<text top="246" left="100" width="17" height="7" font="font11" id="p1_t26" reading_order_no="23" segment_no="10" tag_type="text"><i> et al</i></text>
<text top="246" left="116" width="107" height="7" font="font3" id="p1_t27" reading_order_no="24" segment_no="10" tag_type="text">.; licensee BioMed Central Ltd. </text>
<text top="256" left="57" width="500" height="7" font="font3" id="p1_t28" reading_order_no="25" segment_no="11" tag_type="text">This is an open access article distributed under the terms of the Creative Commons Attribution License<a href="http://creativecommons.org/licenses/by/2.0"> (http://creativecommons.org/licenses/by/2.0), </a></text>
<text top="266" left="57" width="409" height="7" font="font3" id="p1_t29" reading_order_no="26" segment_no="11" tag_type="text">which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</text>
<text top="295" left="57" width="43" height="10" font="font8" id="p1_t30" reading_order_no="27" segment_no="12" tag_type="title"><b>Abstract</b></text>
<text top="316" left="57" width="49" height="8" font="font12" id="p1_t31" reading_order_no="28" segment_no="13" tag_type="text"><b>Introduction</b></text>
<text top="316" left="106" width="14" height="8" font="font13" id="p1_t32" reading_order_no="29" segment_no="13" tag_type="text"> Na</text>
<text top="315" left="120" width="4" height="6" font="font14" id="p1_t33" reading_order_no="30" segment_no="13" tag_type="text">+</text>
<text top="316" left="124" width="10" height="8" font="font13" id="p1_t34" reading_order_no="31" segment_no="13" tag_type="text">/H</text>
<text top="315" left="134" width="6" height="6" font="font14" id="p1_t35" reading_order_no="32" segment_no="13" tag_type="text">+ </text>
<text top="316" left="140" width="117" height="8" font="font13" id="p1_t36" reading_order_no="33" segment_no="13" tag_type="text">exchanger regulatory factor 1 </text>
<text top="316" left="257" width="39" height="8" font="font15" id="p1_t37" reading_order_no="34" segment_no="13" tag_type="text"><i>(NHERF1</i></text>
<text top="316" left="295" width="2" height="8" font="font13" id="p1_t38" reading_order_no="35" segment_no="13" tag_type="text">,</text>
<text top="326" left="57" width="67" height="8" font="font13" id="p1_t39" reading_order_no="36" segment_no="13" tag_type="text">also known as </text>
<text top="326" left="124" width="31" height="8" font="font15" id="p1_t40" reading_order_no="37" segment_no="13" tag_type="text"><i>EBP50 </i></text>
<text top="326" left="159" width="10" height="8" font="font13" id="p1_t41" reading_order_no="38" segment_no="13" tag_type="text">or </text>
<text top="326" left="173" width="30" height="8" font="font15" id="p1_t42" reading_order_no="39" segment_no="13" tag_type="text"><i>NHERF</i></text>
<text top="326" left="203" width="94" height="8" font="font13" id="p1_t43" reading_order_no="40" segment_no="13" tag_type="text">) is a putative tumour</text>
<text top="337" left="57" width="205" height="8" font="font13" id="p1_t44" reading_order_no="41" segment_no="13" tag_type="text">suppressor gene in human breast cancer. Located at </text>
<text top="337" left="262" width="33" height="8" font="font15" id="p1_t45" reading_order_no="42" segment_no="13" tag_type="text"><i>17q25.1</i></text>
<text top="337" left="295" width="2" height="8" font="font13" id="p1_t46" reading_order_no="43" segment_no="13" tag_type="text">,</text>
<text top="347" left="57" width="38" height="8" font="font15" id="p1_t47" reading_order_no="44" segment_no="13" tag_type="text"><i>NHERF1 </i></text>
<text top="347" left="96" width="201" height="8" font="font13" id="p1_t48" reading_order_no="45" segment_no="13" tag_type="text">is frequently targeted during breast tumourigenesis.</text>
<text top="358" left="57" width="140" height="8" font="font13" id="p1_t49" reading_order_no="46" segment_no="13" tag_type="text">Loss of heterozygosity (LOH) at the </text>
<text top="358" left="196" width="38" height="8" font="font15" id="p1_t50" reading_order_no="47" segment_no="13" tag_type="text"><i>NHERF1 </i></text>
<text top="358" left="234" width="63" height="8" font="font13" id="p1_t51" reading_order_no="48" segment_no="13" tag_type="text">locus is found in</text>
<text top="368" left="57" width="194" height="8" font="font13" id="p1_t52" reading_order_no="49" segment_no="13" tag_type="text">more than 50% of breast tumours. In addition, </text>
<text top="368" left="251" width="38" height="8" font="font15" id="p1_t53" reading_order_no="50" segment_no="13" tag_type="text"><i>NHERF1 </i></text>
<text top="368" left="291" width="6" height="8" font="font13" id="p1_t54" reading_order_no="51" segment_no="13" tag_type="text">is</text>
<text top="379" left="57" width="240" height="8" font="font13" id="p1_t55" reading_order_no="52" segment_no="13" tag_type="text">mutated in a subset of primary breast tumours and breast cancer</text>
<text top="389" left="57" width="81" height="8" font="font13" id="p1_t56" reading_order_no="53" segment_no="13" tag_type="text">cell lines. LOH at the </text>
<text top="389" left="138" width="38" height="8" font="font15" id="p1_t57" reading_order_no="54" segment_no="13" tag_type="text"><i>NHERF1 </i></text>
<text top="389" left="175" width="122" height="8" font="font13" id="p1_t58" reading_order_no="55" segment_no="13" tag_type="text">locus is strongly associated with</text>
<text top="400" left="57" width="193" height="8" font="font13" id="p1_t59" reading_order_no="56" segment_no="13" tag_type="text">aggressive features of breast tumours, implicating </text>
<text top="400" left="250" width="38" height="8" font="font15" id="p1_t60" reading_order_no="57" segment_no="13" tag_type="text"><i>NHERF1 </i></text>
<text top="400" left="288" width="9" height="8" font="font13" id="p1_t61" reading_order_no="58" segment_no="13" tag_type="text">as</text>
<text top="410" left="57" width="240" height="8" font="font13" id="p1_t62" reading_order_no="59" segment_no="13" tag_type="text">a haploinsufficiency tumour suppressor gene. However, the</text>
<text top="421" left="57" width="240" height="8" font="font13" id="p1_t63" reading_order_no="60" segment_no="13" tag_type="text">putative NHERF1 tumour suppressor activity has not been</text>
<text top="431" left="57" width="75" height="8" font="font13" id="p1_t64" reading_order_no="61" segment_no="13" tag_type="text">functionally verified.</text>
<text top="452" left="57" width="36" height="8" font="font12" id="p1_t65" reading_order_no="62" segment_no="15" tag_type="text"><b>Methods</b></text>
<text top="452" left="92" width="205" height="8" font="font13" id="p1_t66" reading_order_no="63" segment_no="15" tag_type="text"> To confirm the NHERF1 tumour suppressor activity</text>
<text top="463" left="57" width="240" height="8" font="font13" id="p1_t67" reading_order_no="64" segment_no="15" tag_type="text">suggested by our genetic analyses, we used retrovirus-</text>
<text top="473" left="57" width="240" height="8" font="font13" id="p1_t68" reading_order_no="65" segment_no="15" tag_type="text">transduced short hairpin RNA (shRNA) to knock down NHERF1</text>
<text top="484" left="57" width="240" height="8" font="font13" id="p1_t69" reading_order_no="66" segment_no="15" tag_type="text">expression in breast cancer cell lines MCF7 and T47D. These</text>
<text top="494" left="57" width="154" height="8" font="font13" id="p1_t70" reading_order_no="67" segment_no="15" tag_type="text">cells were then assessed for cell growth </text>
<text top="494" left="210" width="28" height="8" font="font15" id="p1_t71" reading_order_no="68" segment_no="15" tag_type="text"><i>in vitro </i></text>
<text top="494" left="238" width="17" height="8" font="font13" id="p1_t72" reading_order_no="69" segment_no="15" tag_type="text">and </text>
<text top="494" left="255" width="24" height="8" font="font15" id="p1_t73" reading_order_no="70" segment_no="15" tag_type="text"><i>in vivo</i></text>
<text top="494" left="279" width="18" height="8" font="font13" id="p1_t74" reading_order_no="71" segment_no="15" tag_type="text">. The</text>
<text top="505" left="57" width="240" height="8" font="font13" id="p1_t75" reading_order_no="72" segment_no="15" tag_type="text">control and NHERF1 knockdown cells were also serum-starved</text>
<text top="515" left="57" width="240" height="8" font="font13" id="p1_t76" reading_order_no="73" segment_no="15" tag_type="text">and re-fed to compare their cell cycle progression as measured</text>
<text top="526" left="57" width="179" height="8" font="font13" id="p1_t77" reading_order_no="74" segment_no="15" tag_type="text">by fluorescence-activated cell sorting analyses.</text>
<text top="316" left="315" width="31" height="8" font="font12" id="p1_t78" reading_order_no="75" segment_no="14" tag_type="text"><b>Results</b></text>
<text top="316" left="346" width="210" height="8" font="font13" id="p1_t79" reading_order_no="76" segment_no="14" tag_type="text"> We found that downregulation of the endogenous</text>
<text top="326" left="315" width="240" height="8" font="font13" id="p1_t80" reading_order_no="77" segment_no="14" tag_type="text">NHERF1 in T47D or MCF7 cells resulted in enhanced cell</text>
<text top="337" left="315" width="240" height="8" font="font13" id="p1_t81" reading_order_no="78" segment_no="14" tag_type="text">proliferation in both anchorage-dependent and -independent</text>
<text top="347" left="315" width="240" height="8" font="font13" id="p1_t82" reading_order_no="79" segment_no="14" tag_type="text">conditions compared with that of the vector control cells.</text>
<text top="358" left="315" width="241" height="8" font="font13" id="p1_t83" reading_order_no="80" segment_no="14" tag_type="text">NHERF1 knockdown T47D cells implanted at mammary fat</text>
<text top="368" left="315" width="240" height="8" font="font13" id="p1_t84" reading_order_no="81" segment_no="14" tag_type="text">pads of athymic mice formed larger tumours than did control</text>
<text top="379" left="315" width="240" height="8" font="font13" id="p1_t85" reading_order_no="82" segment_no="14" tag_type="text">cells. We found that serum-starved NHERF1 knockdown cells</text>
<text top="389" left="315" width="58" height="8" font="font13" id="p1_t86" reading_order_no="83" segment_no="14" tag_type="text">had a faster G</text>
<text top="393" left="373" width="4" height="6" font="font14" id="p1_t87" reading_order_no="84" segment_no="14" tag_type="text">1</text>
<text top="389" left="377" width="179" height="8" font="font13" id="p1_t88" reading_order_no="85" segment_no="14" tag_type="text">-to-S transition after serum re-stimulation than</text>
<text top="400" left="315" width="240" height="8" font="font13" id="p1_t89" reading_order_no="86" segment_no="14" tag_type="text">the control cells. Immunoblotting showed that the accelerated</text>
<text top="410" left="315" width="241" height="8" font="font13" id="p1_t90" reading_order_no="87" segment_no="14" tag_type="text">cell cycle progression in NHERF1 knockdown cells was</text>
<text top="421" left="315" width="241" height="8" font="font13" id="p1_t91" reading_order_no="88" segment_no="14" tag_type="text">accompanied by increased expression of cyclin E and elevated</text>
<text top="431" left="315" width="96" height="8" font="font13" id="p1_t92" reading_order_no="89" segment_no="14" tag_type="text">Rb phosphorylation level.</text>
<text top="463" left="315" width="46" height="8" font="font12" id="p1_t93" reading_order_no="90" segment_no="16" tag_type="text"><b>Conclusion</b></text>
<text top="463" left="361" width="195" height="8" font="font13" id="p1_t94" reading_order_no="91" segment_no="16" tag_type="text"> Our findings suggested that the normal NHERF1</text>
<text top="473" left="315" width="241" height="8" font="font13" id="p1_t95" reading_order_no="92" segment_no="16" tag_type="text">function in mammary epithelial cells involves blockage of cell</text>
<text top="484" left="315" width="241" height="8" font="font13" id="p1_t96" reading_order_no="93" segment_no="16" tag_type="text">cycle progression. Our study affirmed the tumour suppressor</text>
<text top="494" left="315" width="240" height="8" font="font13" id="p1_t97" reading_order_no="94" segment_no="16" tag_type="text">activity of NHERF1 in breast which may be related to its</text>
<text top="505" left="315" width="241" height="8" font="font13" id="p1_t98" reading_order_no="95" segment_no="16" tag_type="text">regulatory effect on cell cycle. It warrants future investigation of</text>
<text top="515" left="315" width="241" height="8" font="font13" id="p1_t99" reading_order_no="96" segment_no="16" tag_type="text">this novel tumour suppressor pathway in human breast cancer</text>
<text top="526" left="315" width="170" height="8" font="font13" id="p1_t100" reading_order_no="97" segment_no="16" tag_type="text">which may turn up therapeutic opportunities.</text>
<text top="579" left="57" width="64" height="10" font="font8" id="p1_t101" reading_order_no="98" segment_no="18" tag_type="title"><b>Introduction</b></text>
<text top="591" left="57" width="11" height="9" font="font13" id="p1_t102" reading_order_no="99" segment_no="19" tag_type="text">Na</text>
<text top="591" left="68" width="4" height="6" font="font14" id="p1_t103" reading_order_no="100" segment_no="19" tag_type="text">+</text>
<text top="591" left="72" width="10" height="9" font="font13" id="p1_t104" reading_order_no="101" segment_no="19" tag_type="text">/H</text>
<text top="591" left="82" width="6" height="6" font="font14" id="p1_t105" reading_order_no="102" segment_no="19" tag_type="text">+ </text>
<text top="591" left="89" width="123" height="9" font="font13" id="p1_t106" reading_order_no="103" segment_no="19" tag_type="text">exchanger regulatory factor 1 (</text>
<text top="591" left="211" width="36" height="9" font="font15" id="p1_t107" reading_order_no="104" segment_no="19" tag_type="text"><i>NHERF1</i></text>
<text top="591" left="247" width="50" height="9" font="font13" id="p1_t108" reading_order_no="105" segment_no="19" tag_type="text">, also known</text>
<text top="603" left="57" width="12" height="9" font="font13" id="p1_t109" reading_order_no="106" segment_no="19" tag_type="text">as </text>
<text top="603" left="70" width="35" height="9" font="font15" id="p1_t110" reading_order_no="107" segment_no="19" tag_type="text"><i>EBP-50 </i></text>
<text top="603" left="107" width="10" height="9" font="font13" id="p1_t111" reading_order_no="108" segment_no="19" tag_type="text">or </text>
<text top="603" left="120" width="31" height="9" font="font15" id="p1_t112" reading_order_no="109" segment_no="19" tag_type="text"><i>NHERF</i></text>
<text top="603" left="151" width="147" height="9" font="font13" id="p1_t113" reading_order_no="110" segment_no="19" tag_type="text">) is a candidate tumour suppressor</text>
<text top="614" left="57" width="240" height="9" font="font13" id="p1_t114" reading_order_no="111" segment_no="19" tag_type="text">gene in human breast cancer<a href=""> [1].</a> We reported loss of hetero-</text>
<text top="626" left="57" width="85" height="9" font="font13" id="p1_t115" reading_order_no="112" segment_no="19" tag_type="text">zygosity (LOH) at the </text>
<text top="626" left="142" width="39" height="9" font="font15" id="p1_t116" reading_order_no="113" segment_no="19" tag_type="text"><i>NHERF1 </i></text>
<text top="626" left="181" width="48" height="9" font="font13" id="p1_t117" reading_order_no="114" segment_no="19" tag_type="text">gene locus (</text>
<text top="626" left="229" width="34" height="9" font="font15" id="p1_t118" reading_order_no="115" segment_no="19" tag_type="text"><i>17q25.1</i></text>
<text top="626" left="263" width="34" height="9" font="font13" id="p1_t119" reading_order_no="116" segment_no="19" tag_type="text">) in more</text>
<text top="638" left="57" width="240" height="9" font="font13" id="p1_t120" reading_order_no="117" segment_no="19" tag_type="text">than 50% of human breast tumours. Such loss is infrequent,</text>
<text top="650" left="57" width="194" height="9" font="font13" id="p1_t121" reading_order_no="118" segment_no="19" tag_type="text">however, in other tumour types, suggesting that </text>
<text top="650" left="251" width="39" height="9" font="font15" id="p1_t122" reading_order_no="119" segment_no="19" tag_type="text"><i>NHERF1 </i></text>
<text top="650" left="291" width="6" height="9" font="font13" id="p1_t123" reading_order_no="120" segment_no="19" tag_type="text">is</text>
<text top="661" left="57" width="240" height="9" font="font13" id="p1_t124" reading_order_no="121" segment_no="19" tag_type="text">specifically targeted during mammary tumourigenesis. In a</text>
<text top="673" left="57" width="240" height="9" font="font13" id="p1_t125" reading_order_no="122" segment_no="19" tag_type="text">panel of breast tumours pre-screened for LOH, three intra-</text>
<text top="559" left="315" width="77" height="9" font="font13" id="p1_t126" reading_order_no="123" segment_no="17" tag_type="text">genic mutations of </text>
<text top="559" left="392" width="39" height="9" font="font15" id="p1_t127" reading_order_no="124" segment_no="17" tag_type="text"><i>NHERF1 </i></text>
<text top="559" left="432" width="124" height="9" font="font13" id="p1_t128" reading_order_no="125" segment_no="17" tag_type="text">were found (approximately 3%)</text>
<text top="571" left="315" width="67" height="9" font="font13" id="p1_t129" reading_order_no="126" segment_no="17" tag_type="text"><a href="">[1]. LOH at the </a></text>
<text top="571" left="382" width="39" height="9" font="font15" id="p1_t130" reading_order_no="127" segment_no="17" tag_type="text"><i>NHERF1 </i></text>
<text top="571" left="422" width="134" height="9" font="font13" id="p1_t131" reading_order_no="128" segment_no="17" tag_type="text">locus is positively correlated with</text>
<text top="583" left="315" width="241" height="9" font="font13" id="p1_t132" reading_order_no="129" segment_no="17" tag_type="text">aggressive features of breast tumours, including tumour size,</text>
<text top="595" left="315" width="240" height="9" font="font13" id="p1_t133" reading_order_no="130" segment_no="17" tag_type="text">grade, and stage. The association indicates a critical role for</text>
<text top="606" left="315" width="39" height="9" font="font15" id="p1_t134" reading_order_no="131" segment_no="17" tag_type="text"><i>NHERF1 </i></text>
<text top="606" left="356" width="200" height="9" font="font13" id="p1_t135" reading_order_no="132" segment_no="17" tag_type="text">in mammary carcinogenesis, in which its putative</text>
<text top="618" left="315" width="240" height="9" font="font13" id="p1_t136" reading_order_no="133" segment_no="17" tag_type="text">suppressor activity is haploinsufficient. The haploinsufficiency</text>
<text top="630" left="315" width="26" height="9" font="font13" id="p1_t137" reading_order_no="134" segment_no="17" tag_type="text">of the </text>
<text top="630" left="341" width="39" height="9" font="font15" id="p1_t138" reading_order_no="135" segment_no="17" tag_type="text"><i>NHERF1 </i></text>
<text top="630" left="380" width="175" height="9" font="font13" id="p1_t139" reading_order_no="136" segment_no="17" tag_type="text">gene may explain its relatively low frequency</text>
<text top="642" left="315" width="91" height="9" font="font13" id="p1_t140" reading_order_no="137" segment_no="17" tag_type="text">of intragenic mutations.</text>
<text top="695" left="57" width="499" height="7" font="font3" id="p1_t141" reading_order_no="138" segment_no="20" tag_type="footnote">ER = oestrogen receptor; ERE = oestrogen response element; ERM = ezrin-radixin-moesin; FACS = fluorescence-activated cell sorting; FBS = foetal </text>
<text top="705" left="57" width="499" height="7" font="font3" id="p1_t142" reading_order_no="139" segment_no="20" tag_type="footnote">bovine serum; LOH = loss of heterozygosity; MTT = 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; NF2 = neurofibromatosis-2; NHE3 </text>
<text top="714" left="57" width="17" height="7" font="font3" id="p1_t143" reading_order_no="140" segment_no="20" tag_type="footnote">= Na</text>
<text top="714" left="74" width="4" height="5" font="font14" id="p1_t144" reading_order_no="141" segment_no="20" tag_type="footnote">+</text>
<text top="714" left="78" width="8" height="7" font="font3" id="p1_t145" reading_order_no="142" segment_no="20" tag_type="footnote">/H</text>
<text top="714" left="86" width="5" height="5" font="font14" id="p1_t146" reading_order_no="143" segment_no="20" tag_type="footnote">+ </text>
<text top="714" left="91" width="123" height="7" font="font3" id="p1_t147" reading_order_no="144" segment_no="20" tag_type="footnote">exchanger isoform 3; NHERF1 = Na</text>
<text top="714" left="215" width="4" height="5" font="font14" id="p1_t148" reading_order_no="145" segment_no="20" tag_type="footnote">+</text>
<text top="714" left="218" width="9" height="7" font="font3" id="p1_t149" reading_order_no="146" segment_no="20" tag_type="footnote">/H</text>
<text top="714" left="227" width="5" height="5" font="font14" id="p1_t150" reading_order_no="147" segment_no="20" tag_type="footnote">+ </text>
<text top="714" left="232" width="313" height="7" font="font3" id="p1_t151" reading_order_no="148" segment_no="20" tag_type="footnote">exchanger regulatory factor 1; PBS = phosphate-buffered saline; PDGFR = platelet-derived </text>
<text top="724" left="57" width="499" height="7" font="font3" id="p1_t152" reading_order_no="149" segment_no="20" tag_type="footnote">growth factor receptor; PDZ = PSD-95/Dlg/ZO1; PTEN = phosphatase and tensin homologue (mutated in multiple advanced cancers 1); shRNA = </text>
<text top="733" left="57" width="166" height="7" font="font3" id="p1_t153" reading_order_no="150" segment_no="20" tag_type="footnote">short hairpin RNA; SYK = spleen tyrosine kinase.</text>
</page>
</pdf2xml>
